M. Dror Michaelson

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115)

  International Journal of Radiation Oncology*Biology*Physics · 2025-07-23

• Open pilot of a culturally responsive, cognitive-behavioral intervention (PROWESS) for Black and Latino men receiving androgen deprivation therapy for prostate cancer.

  Journal of Clinical Oncology · 2025-05-28

• Circulating tumor cell RNA biomarker for bavdegalutamide (ARV-110) in metastatic castration-resistant prostate cancer without AR T878/H875 mutations.

  Journal of Clinical Oncology · 2025-02-10 · 1 citations

• Updated results from the phase 2 LITESPARK-003 study of belzutifan plus cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).

  Journal of Clinical Oncology · 2025-02-10 · 5 citations

• Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study

  The Lancet Oncology · 2025-01-01 · 21 citations

• Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926

  Journal of Clinical Oncology · 2024-09-03 · 23 citations

• 1994P Updated efficacy profile of the double antibody drug conjugate (DAD) phase I trial: Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) in ≥ second line in metastatic urothelial carcinoma (mUC)

  Annals of Oncology · 2024-09-01 · 1 citations